Abstract
The United States sells $3.0 billion of pesticides and $7.0 billion of pharmaceuticals to consumers in export markets. Many of these products are banned and/or unapproved for use within the United States. This perplexing double standard continues to create unique ethical questions for United States based multinational corporations (MNCs) who sell pesticides and pharmaceutical products worldwide. This paper explores the issues related to export sales and how to effectively control and monitor the sale of these products to customers in developing countries.

This publication has 0 references indexed in Scilit: